• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis: Is There an Association Between TXA and Increased Risk for Thromboembolic Events?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Tranexamic acid (TXA), an antifibrinolytic drug, has proven valuable in reducing bleeding-associated deaths due to trauma, postpartum hemorrhage, and traumatic brain injury
    • However, concerns remain regarding risk for vascular occlusive events
  • Taeuber et al. (JAMA Surg., 2021) examined the association between IV TXA and total thromboembolic events (TEs) and mortality

METHODS:

  • Systematic review and meta-analysis
  • Data sources
    • Cochrane Central Register of Controlled Trials and MEDLINE between 1976 and 2020
  • Study inclusion criteria
    • RCTs
    • Trials that compared IV TXA with placebo or no treatment
    • Excluded: Studies that administered only oral or topical TXA
  • Primary outcomes
    • Vascular occlusive events
    • Mortality

RESULTS:

  • 216 trials | 125,550 patients
  • Total TEs
    • TXA: 2.1%
    • Control: 2.0%
  • Dosing highly variable: From 0.5 to 5 g or 10 to 100 mg/kg
  • There was no association between TXA and risk of TEs
    • Risk difference 0.001 (95% CI, −0.001 to 0.002; P=0.49)
  • There was also no association between TXA and risk for
    • Venous thrombosis | PE | VTEs | Myocardial infarction or ischemia | Cerebral infarction or ischemia
  • Administration of TXA
    • Was associated with reduction in overall mortality and bleeding mortality (both P<.001)
    • Was not associated with reduction in risk of nonbleeding mortality (P=.29)
  • There was no increased risk of vascular occlusive events even in studies including patients with a history of thromboembolism
  • There was no association between TXA and incidence of total TEs across studies with varying sample sizes
    • Sample size ≤99
      • Risk difference 0.004 (95% CI, −0.006 to 0.014; P=0.40)
    • Sample size 100 to 999
      • Risk difference 0.004 (95% CI, −0.003 to 0.011; P=0.26)
    • Sample size ≥1000
      • Risk difference −0.001 (95% CI, −0.003 to 0.001; P=0.44)
  • There was no association between TXA dosing and risk for venous TEs
    • Risk difference −0.005 (95% CI, −0.021 to 0.011; P=0.53)

CONCLUSION:

  • There is no association between IV TXA and increased risk for any thromboembolic events
    • This remained true even at different levels of TXA dosing and in studies of varying sample sizes
  • TXA was associated with a reduction in risk of overall and bleeding-related mortality
  • The authors conclude

Taken as a whole, this systematic review and meta-analysis did not find that intravenous treatment with TXA in patients of any medical discipline was associated with a significant increased risk for TEs irrespective of administered dose

Learn More – Primary Sources:

Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Results From the Landmark Trial on Tranexamic Acid for Postpartum Hemorrhage
Meta-Analysis of Topical TXA to Reduce Surgical Blood Loss
Single IV Dose of TXA Prior to Surgery: Safety and Efficacy Review

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site